Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sabrina Ribeli-Hofmann"'
Autor:
R.A. Soo, J.-Y. Han, U. Dafni, B.C. Cho, C.M. Yeo, E. Nadal, E. Carcereny, J. de Castro, M.A. Sala, R. Bernabé, L. Coate, M. Provencio Pulla, R. Garcia Campelo, S. Cuffe, S.M.S. Hashemi, M. Früh, B. Massuti, J. Garcia-Sanchez, M. Dómine, M. Majem, J.-M. Sanchez-Torres, C. Britschgi, M. Pless, G. Dimopoulou, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R.A. Stahel, S. Peters, Rolf Stahel, Solange Peters, Ross Soo, Ji-Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki-Voser, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Susanne Roux, Magdalena Sanchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, Martin Reist, Priska Rentsch, Sinead Cuffe, Sayed Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario Garcia Campelo, Bartomeu Massutí, Jose Garcia, Manuel Dómine, Margarita Majem, Jose Miguel Sanchez, Christian Britschgi, Miklos Pless, Chong Ming Yeo, Byoung Chul Cho
Publikováno v:
ANNALS OF ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
Background: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M
Autor:
Barbara Ruepp, Rupert Bartsch, Andrea Gombos, Frances M. Boyle, Giuseppe Viale, Anita Hiltbrunner, Thomas Bachelot, Martine Piccart-Gebhart, Caitlin Mahoney, Debora Fumagalli, Rina Hui, Theodora Goulioti, Fabrice Andre, Marco Colleoni, Carmen Comune, Magdelena Weber, Michelle Jenkins, Stefan Aebi, Stefania Andrighetto, Stamatina Fournarakou, Meredith M. Regan, Colleen King, Angelo Di Leo, Alan S. Coates, Rita Hui, Aron Goldhirsch, Mario Campone, Per Karlsson, Rolf A. Stahel, Vassiliki Karantza, Hui Huang, Laura Biganzoli, Hervé Bonnefoi, Sabrina Ribeli-Hofmann, Roswitha Kammler, Magdalena Sánchez-Hohl, Karolyn Scott, Patrick Schneier, Giuseppe Curigliano, Ingrid Kössler, Sherene Loi, Heather Findlay, Richard D. Gelber, Holly Shaw, Guy Jerusalem, Susan Fischer, Anita Giobbie-Hurder, Daniela Celotto, Manuela Rabaglio-Poretti, Rita Pfister, Michela Frapolli, Monica Greco, Adriana Gasca, Mark J. Smyth, Jaime A. Mejia, Karen N. Price, Heidi Roschitzki, Rudolf Maibach
Publikováno v:
The Lancet Oncology. 20:371-382
Summary Background HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tum